---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-046536"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:18:39.257430+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26

## Summary
- Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).
- Cash & investments $706M at Dec 31, 2025 vs $903M a year earlier; burn reflects Phase 3 ramp.
- VANQUISH-1 (obesity) enrollment completed >4,500 ahead of schedule; VANQUISH-2 (obesity+diabetes) near full.
- Oral VK2735 to advance to Phase 3 in 3Q26 after FDA end-of-Phase 2 meeting; maintenance dosing data due 3Q26.
- IND filing for novel amylin agonist planned in 1Q26; Phase 1 maintenance study fully enrolled.

## SEC filing metadata
- accession: 0001193125-26-046536
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/0001193125-26-046536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-046536
- JSON: https://secwatch.observer/filing/0001193125-26-046536.json
- Plain text: https://secwatch.observer/filing/0001193125-26-046536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.